Skip to main content
. Author manuscript; available in PMC: 2017 Aug 23.
Published in final edited form as: J Control Release. 2017 Mar 29;254:131–136. doi: 10.1016/j.jconrel.2017.03.387

Figure 4. Protein delivery comparison between PTDM 1–2 and commercially available reagents in Jurkat T cells in serum-containing media.

Figure 4

Percentage of EGFP positive cells after 4 h of treatment with EGFP complexed with either PTDM 1–2 or one of the commercially available reagents (60 nM EGFP; complete media). Each commercial reagent was used at the company recommended ratio. Values and error bars represent the mean ± SEM of at least three independent experiments.